Pharmaceutical engineering encompasses the development of new drugs, the design of drug delivery systems, and the improvement of drug manufacturing processes.

Implants are not a common type of drug delivery system, as they require surgical insertion and are typically used for long-term drug delivery.

Bioavailability studies are conducted to determine the rate at which a drug is absorbed into the body, the maximum concentration of a drug in the body, and the duration of action of a drug.

The age of the patient is not a factor that can affect the bioavailability of a drug.

Clinical trials are conducted to evaluate the safety and efficacy of a new drug, to determine the optimal dosage of a new drug, and to compare a new drug to an existing drug.

Phase IV is not a phase of a clinical trial. Phase I trials involve a small number of healthy volunteers, Phase II trials involve a larger number of patients with the disease or condition being treated, and Phase III trials involve a large number of patients with the disease or condition being treated.

Pharmacokinetic studies are conducted to determine the rate at which a drug is absorbed into the body, the maximum concentration of a drug in the body, and the duration of action of a drug.

The age of the patient is not a factor that can affect the pharmacokinetics of a drug.

Pharmacodynamic studies are conducted to determine the effects of a drug on the body, to determine the dose-response relationship of a drug, and to determine the safety of a drug.

Clinical trials are not a type of pharmacodynamic study. In vitro studies are conducted in the laboratory, in vivo studies are conducted in living organisms, and animal studies are conducted in animals.

Drug discovery programs are conducted to identify new drug targets, to develop new drug candidates, and to evaluate the safety and efficacy of new drugs.

Clinical trials are not a step in the drug discovery process. Target identification, lead generation, and lead optimization are all steps in the drug discovery process.

Drug development programs are conducted to develop new drugs, to evaluate the safety and efficacy of new drugs, and to obtain regulatory approval for new drugs.

Marketing is not a step in the drug development process. Preclinical studies, clinical trials, and regulatory submission are all steps in the drug development process.

Regulatory submissions are conducted to obtain approval to market a new drug, to provide information about the safety and efficacy of a new drug, and to comply with government regulations.